Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ganitumab - Amgen

Drug Profile

Ganitumab - Amgen

Alternative Names: AMG-479

Latest Information Update: 09 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Millennium; NantWorks; National Cancer Institute (USA); Novartis; Takeda; Takeda Oncology; UCLAs Jonsson Comprehensive Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ewing's sarcoma
  • Phase II Solid tumours
  • Phase Unknown Rhabdomyosarcoma
  • No development reported Breast cancer; Colorectal cancer; Sarcoma; Small cell lung cancer
  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 22 Oct 2019 In November 2019, Dana Farber Cancer Institute plans a phase II trial for Ewing Sarcoma (In children, in adult, second-line therapy or greater) in the US (NCT04129151)
  • 26 Mar 2019 NantCell completes an expanded access programme in Ewing's Sarcoma (Monotherapy, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT03029481)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top